A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the safety of different dose strengths of INX-08189 in healthy adults. The study will also look at how rapidly the drug breaks down in the body (pharmacokinetics or PK). The study objectives include: To evaluate the safety of single ascending oral doses of INX-08189 in healthy subjects To characterize the pharmacokinetic (PK) profile of single ascending oral doses of INX-08189 in healthy subjects To assess the food effect on the PK of a single oral dose of INX-08189

Official Title
-----------------
A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: INX-08189
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy men and post-menopausal (absence of periods for more than 2 years) surgically sterile, or non-pregnant, non-lactating women using a reliable form of contraception (see Inclusion Criteria 9) Age 18 to 65 years, inclusive Normal (no clinically significant abnormalities) laboratory tests (chemistry, hematology and urinalysis) No clinically significant abnormalities on ECG (QTcB interval must be < 450 ms) Weight ≥ 50kg and Body Mass Index (BMI) of 19 to 30, inclusive Negative urine drug screen at screening and on Study Day -1 Negative serum βHCG pregnancy test at screening and on Study Day -1 (for all women) Hepatitis B surface antigen, hepatitis C antibody, and HIV antibody negative Agreement to practice a barrier method of birth control plus the use of a spermicide throughout the study period by both male and female subjects (oral contraceptives are not permitted) Able to complete all study visits Signed informed consent form (ICF) Exclusion Criteria: Any active medical problem for which the subject is being evaluated and/or treated Calculated creatinine clearance (calculated using the IDMS traceable equation for the MDRD value) < 50 mL/min/1.73 m2 Regular use of medications, prescription or non-prescription; no medication may be taken within 1 week prior to study dosing Use of alcohol within 48 hours prior to dosing (subjects must also agree to not use alcohol for 96 hours after dosing) Current lactation or breastfeeding Major surgery within 30 days prior to dosing Receipt of an investigational drug within 30 days prior to dosing Donation of blood or plasma within 30 days prior to dosing Any other problem, that in the opinion of the Investigator, will affect the safety of the subject or outcome of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: INX-08189<br> | Drug: INX-08189<br>* 3, 25 and 100 mg capsules; oral administration, single dose<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* matching placebo capsules, oral administration, single dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the safety of single ascending oral doses of INX-08189 in healthy subjects | Safety will be evaluated on the basis of adverse event (AE) incidence, changes in serum chemistry and hematology values, urinalysis results, and changes in vital signs and in electrocardiogram (ECG) findings. | periodically over 14 days | 
| Characterize the pharmacokinetic (PK) profile of single ascending oral doses of INX-08189 in healthy subjects | Including a determination of maximum observed plasma concentration (Cmax), time at which the maximum plasma concentration was observed (Tmax), time at which concentrations are first measurable in the plasma (Tlag), area under the plasma concentration-time curve from time 0 to time of last measurable plasma concentration (AUC 0-last) and elimination half-life (T 1/2) after single ascending oral doses. | periodically over 14 days | 
| Assess the effect of a high fat meal on the PK parameters | The effect of food (standard high-fat meal) on the absorption of INX-08189 will be evaluated | periodically over 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety and Pharmacokinetics